Brain

LifeWave Launches Cellergize™ Evening: Nighttime Supplement for Relaxation, Recovery, and Restorative Sleep

The New Formula Joins the $11.8 Billion Global Sleep and Recovery Supplement Market as Part of theBrand's Growing Collection of…

2 months ago

CEFALY Marks a Milestone: #1 Neuromodulation Device Prescribed by Veterans Health Administration Providers

DARIEN, Conn., Nov. 3, 2025 /PRNewswire/ -- Medical device maker CEFALY Technology announced today that CEFALY Connected has become the…

2 months ago

Connecticut Innovations Invests $11.3 Million in Early-Stage Companies in Q1 FY26

Deals leveraged $86.9 million in outside capital in the first quarter of the fiscal year NEW HAVEN, Conn., Nov. 3,…

2 months ago

All In for Awareness: November Marks National Epilepsy Awareness Month

BOWIE, Md., Nov. 3, 2025 /PRNewswire/ -- The Epilepsy Foundation of America (EFA) is calling on people across the country…

2 months ago

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully ConcludedDSMC Completes Final Review of Cytisinicline, Finds No Drug…

2 months ago

Snke Unveils SnkeXR, the First Medical Grade, Open Platform AR Glasses for Healthcare

Augmented Reality Glasses Purpose-Built for the Medical Technology IndustryMUNICH & HYATTSVILLE, Md.--(BUSINESS WIRE)--#AIHealthcare--MDIC Medical XR Summit – Snke OS GmbH…

2 months ago

Brainomix Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

American Heart Association consortium advances development of evidence-based health tech solutions CHICAGO and OXFORD, England, Oct. 31, 2025 /PRNewswire/ --…

2 months ago

GITEX GLOBAL 2025: Record international participation and outcome-driven dialogues close landmark 45th edition

Unprecedented global turnout defined 2025 edition as 6,800 tech enterprises, 2,000 startups, 1,200 investors, and tech representatives from 180 nations…

2 months ago

ChemDiv’s Discovery Platform Enables Differentiated, Reversible Pan‑EGFR Kinase Inhibitors for GFR‑Mutant Lung Cancer

Upgraded design + synthesis engine targets broad mutant coverage with wild‑type EGFR sparing; active collaboration advances toward scale‑up and CMC…

2 months ago